IMAGE: Lung squamous cell carcinoma

Breaking News

Key: Meeting M      Journal J      Funder F

Showing releases 126-150 out of 1352.

<< < 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 > >>

Public Release: 8-Jun-2016
American Journal of Pathology
New study lays groundwork for potential new anti-cancer therapy
Identifying the cell of origin is crucial to understanding how a tumor develops and metastasizes and for developing targeted therapies. Researchers have found evidence supporting a lymphatic endothelium origin for angiomyolipoma (AML) and lymphangioleiomyomatosis (LAM), two related tumors with previously unknown cellular origins. Furthermore, the newly identified lymphatic endothelial lineage shows translational potential for pharmaceutical treatment. Their findings are published in The American Journal of Pathology.
National Institutes of Health

Contact: Eileen Leahy
ajpmedia@elsevier.com
732-238-3628
Elsevier Health Sciences

Public Release: 8-Jun-2016
Journal of Molecular Diagnostics
New mutation-testing technology has potential to guide targeted lung and colorectal cancer therapies
A new technology suitable for practical clinical testing can detect KRAS gene mutations in lung and colorectal cancers and could thereby facilitate targeted therapies, according to a new report in The Journal of Molecular Diagnostics.
NIH/National Cancer Institute, University of Virginia Cancer Center

Contact: Eileen Leahy
jmdmedia@elsevier.com
732-238-3628
Elsevier Health Sciences

Public Release: 7-Jun-2016
Radiology
New approach to MRI imaging links saturated fats to breast cancer in postmenopausal women
High saturated fats in breast tissue may be an indicator of cancer in postmenopausal women, a study shows.
National Institutes of Health

Contact: Jamie Liptack
jamie.liptack@nyumc.org
212-404-4279
NYU Langone Medical Center / New York University School of Medicine

Public Release: 7-Jun-2016
American Society of Clinical Oncology (ASCO) Annual Meeting
Early detection, smaller cancer among benefits of skin cancer screening at PCP visits
Skin cancer screenings performed by primary care physicians (PCPs) during routine office visits improve the detection of potentially deadly melanomas and find them in earlier stages, according to new research from the University of Pittsburgh School of Medicine. The results were presented today at the 52nd annual American Society of Clinical Oncology (ASCO) annual meeting in Chicago.
National Cancer Institute

Contact: Allison Hydzik
HydzikAM@upmc.edu
412-647-9975
University of Pittsburgh Schools of the Health Sciences

Public Release: 7-Jun-2016
Radiology
Saturated fatty acids linked to breast cancer in postmenopausal women
Fatty acids in the breast may be useful indicators of cancer in postmenopausal women, according to a new study published online in the journal Radiology. The results may help researchers determine the underlying mechanisms behind breast cancer development in some patients.
National Institutes of Health

Contact: Linda Brooks
lbrooks@rsna.org
630-590-7762
Radiological Society of North America

Public Release: 7-Jun-2016
Journal of Medical Devices
Chemical 'sponges' designed to soak up toxic cancer-fighting drugs after targeting tumors
Researchers are creating materials for a cancer treatment system that can limit the side effects of chemotherapy drugs by quickly removing them from the body after use.

Contact: Glenn Roberts Jr.
geroberts@lbl.gov
510-486-5582
DOE/Lawrence Berkeley National Laboratory

Public Release: 7-Jun-2016
American Society for Pharmacology and Experimental Therapeutics
Benefits to timing chemotherapy to body's 'awake' time
Not a morning person? Neither are your kidneys. Research from the Washington State University College of Pharmacy suggests there may be benefits to timing chemotherapy in cancer patients to the time of day the body is 'most awake.'

Contact: Shobhan Gaddameedhi
shobhan.gaddameedhi@wsu.edu
509-368-6570
Washington State University

Public Release: 7-Jun-2016
PLOS Computational Biology
Scientists use modelling to show the role of metabolism and signaling in cancer metastasis
Researchers have built a model to investigate the metastasis of cancer by examining the metabolism of breast epithelial cells and look at the role of signaling. This research, published in PLOS Computational Biology, may contribute to the development of cell specific anti-cancer interventions.

Contact: Ottar Rolfsson
ottarr@hi.is
PLOS

Public Release: 7-Jun-2016
Nature Communications
New types of blood cancer discovered in children
Through a detailed study of leukaemia cells from more than 200 children, a research group at Lund University in Sweden has discovered two new types of childhood leukaemia. Using next-generation sequencing technology (NGS), the researchers were able to study the genome of cancer cells, which is how they discovered the new types of cancer.
Swedish Childhood Cancer Foundation, Swedish Cancer Society, Swedish Research Council, Faculty of Medicine at Lund University and Region Skåne

Contact: Cecilia Schubert
cecilia.schubert@kommunikation.lu.se
46-073-062-3858
Lund University

Public Release: 7-Jun-2016
Spine
Study questions cancer link with bone growth factor for spinal surgery
Adding to previous evidence, a study based on a statewide cancer database shows no increase in cancer risk in patients undergoing spinal fusion surgery with the bone-promoting growth factor recombinant human bone morphogenetic protein. The study appears in Spine, published by Wolters Kluwer.

Contact: Connie Hughes
Connie.Hughes@wolterskluwer.com
646-674-6348
Wolters Kluwer Health

Public Release: 7-Jun-2016
Journal of Nuclear Medicine
Predicting advanced prostate cancer outcomes with NaF-PET/CT
A recent pilot study reported in the June issue of The Journal of Nuclear Medicine found that sodium fluoride (Na-F-18) positron emission tomography/computed tomography (NaF-PET/CT) accurately detects bone metastases in patients with advanced prostate cancer, and follow-up scans over time correlate clearly with clinical outcomes and patient survival.
NIH/National Cancer Institute

Contact: Laurie Callahan
lcallahan@snmmi.org
Society of Nuclear Medicine

Public Release: 7-Jun-2016
Journal of National Cancer Institute
Survival correlation for low versus high enrolling institutions for patients with LA-NSCLC
A secondary analysis of NRG Oncology's clinical trial RTOG 0617, published in the Journal of the National Cancer Institute, was initiated in an effort to evaluate the effect of institution accrual volume on clinical outcomes among patients receiving chemoradiation for locally advanced non-small cell lung cancer (LA-NSCLC).
NIH/National Cancer Institute, Bristol-Myers Squibb

Contact: Angela LaPenta
lapentaa@nrgoncology.org
215-574-3194
NRG Oncology

Public Release: 6-Jun-2016
American Society of Clinical Oncology (ASCO) Annual Meeting
Doctors unleash new weapon to fight pediatric neuroblastoma
After the first year of receiving the novel treatment combination, more than half of children with relapsed neuroblastoma saw either a complete or partial remission -- a 53 percent response rate compared to the typical 10 to 12 percent response rate.
National Institutes of Health

Contact: Beata Mostafavi
bmostafa@umich.edu
734-764-2220
University of Michigan Health System

Public Release: 6-Jun-2016
Proceedings of the National Academy of Sciences
Unexpected function of small nucleolar RNAs explains cause of some diseases
Scientists have discovered unexpected functions of small nucleolar RNAs (snoRNAs) that explain the cause of some diseases. They found that snoRNAs not only modify ribosomes, but can also regulate alternative splicing. Through this second function, they regulate protein function and inhibit the generation of wrong protein variants. Thus, upon the loss of snoRNAs the formation of wrong protein variants can no longer be prevented, leading to diseases like Prader-Willi syndrome and several cancers.
American Heart Association, Ministerio de Economía y Competitividad, Spanish Government, Consolider RNAREG, Sandra Ibarra Foundation for Cancer, Agència de Gestió d'Ajuts Universitaris i de Recerca, USA-Israel Bination

Contact: Dov Smith
dovs@savion.huji.ac.il
972-258-82844
The Hebrew University of Jerusalem

Public Release: 6-Jun-2016
American Society of Clinical Oncology (ASCO) Annual Meeting
Immunotherapy improves survival, quality of life in rapidly progressing head and neck cancer
Immunotherapy doubles overall survival and improves quality of life, with fewer side effects, in a treatment-resistant and rapidly progressing form of head and neck carcinoma, reports a large, randomized international trial co-led by investigators at the University of Pittsburgh Cancer Institute. The new trial was considered so successful that it was stopped early to allow patients in the chemotherapy group to receive the new drug.
Bristol-Myers Squibb

Contact: Allison Hydzik
HydzikAM@upmc.edu
412-647-9975
University of Pittsburgh Schools of the Health Sciences

Public Release: 6-Jun-2016
American Society of Clinical Oncology (ASCO) Annual Meeting
Advanced cancer patients receive aggressive care at high rates at the end of life
A national health claims analysis of cancer patients who were younger than age 65 and had metastatic disease revealed that nearly two-thirds were admitted to the hospital or visited the emergency room in the last 30 days of their lives. The UNC Lineberger Comprehensive Cancer Center researchers who led the study also found that nearly a third of patients died in the hospital.

Contact: Bill Schaller
bill_schaller@med.unc.edu
617-233-5507
University of North Carolina at Chapel Hill

Public Release: 6-Jun-2016
American Society of Clinical Oncology (ASCO) Annual Meeting
Cancer drug trial success
The successful results of a University of Liverpool led drug trial aimed at developing new therapeutic approaches to cancer have been presented at two American medical conferences.

Contact: Nicola Frost
nicola.frost@liverpool.ac.uk
University of Liverpool

Public Release: 6-Jun-2016
Journal of Clinical Investigation
Targeting B-cell malignancies with κ-specific T cells can lead to complete clinical responses
Targeting the light chain expressed by malignant B cells killed tumor cells while sparing normal B cells expressing the other type of light chain.

Contact: Dipali Pathak
pathak@bcm.edu
713-798-4710
Baylor College of Medicine

Public Release: 6-Jun-2016
Annals of the New York Academy of Sciences
War and peace in the human gut: Probing the microbiome
In research appearing in the current issue of Annals of the New York Academy of Science, Aktipis and her colleagues Helen Wasielewski (ASU's Department of Psychology), and Joe Alcock, (at the University of New Mexico Department of Emergency Medicine), examine the role of microbes in the gut. Their study explores how dietary choices promote cooperation or might fuel conflict between gut microbes and the humans they interact with, maintaining health or encouraging the onset of disease.

Contact: Joseph Caspermeyer
Joseph.Caspermeyer@asu.edu
Arizona State University

Public Release: 6-Jun-2016
JAMA Oncology
Personalized medicine leads to better outcomes for patients with cancer
In a meta-analysis of hundreds of clinical trials involving thousands of patients, researchers at University of California San Diego School of Medicine report that therapeutic approaches using precision medicine, which emphasizes the use of individual genetics to refine cancer treatment, showed improved response and longer periods of disease remission, even in phase I trials.
Joan and Irwin Jacobs Fund

Contact: Yadira Galindo
ygalindo@ucsd.edu
619-543-6163
University of California - San Diego

Public Release: 6-Jun-2016
Journal of the American Chemical Society
A new approach to chemical synthesis
MIT chemists have devised a new way to synthesize communesins -- fungal compounds with anti-cancer potential.
National Institutes of Health, National Science Foundation

Contact: Sarah McDonnell
s_mcd@mit.edu
617-253-8923
Massachusetts Institute of Technology

Public Release: 6-Jun-2016
American Society of Clinical Oncology (ASCO) Annual Meeting
Moffitt researchers present phase 1 study results of selinexor combination therapy; multiple myeloma
Moffitt Cancer Center will present results from a phase 1 study of selinexor in combination with liposomal doxorubicin and dexamethasone in patients with relapsed and refractory multiple myeloma. The findings will be discussed Monday, June 6, during the American Society of Clinical Oncology Annual Meeting in Chicago.

Contact: Lisa Chillura
lisa.chillura@moffitt.org
813-745-1353
H. Lee Moffitt Cancer Center & Research Institute

Public Release: 6-Jun-2016
Journal of Clinical Oncology
Methotrexate exposure impacts cognitive processes cancer survivors need to multitask
St. Jude Children's Research Hospital reports that higher blood concentrations of methotrexate during cancer treatment are associated with brain changes and impaired executive function in survivors of pediatric leukemia.
NIH/National Institute of Mental Health, ALSAC

Contact: Frannie Marmorstein
frannie.marmorstein@stjude.org
901-595-0221
St. Jude Children's Research Hospital

Public Release: 6-Jun-2016
Oncotarget
Blood-born molecules could predict those who will develop liver cancer
A panel of microRNAs from blood samples may predict patients at high risk of developing a common liver cancer from hepatitis B virus infection.

Contact: Edyta Zielinska
edyta.zielinska@jefferson.edu
215-955-5291
Thomas Jefferson University

Public Release: 6-Jun-2016
American Society of Clinical Oncology Annual Meeting
Study may help reassure women taking tamoxifen for breast cancer
A study presented at ASCO may help reassure patients who worry the breast cancer drug tamoxifen could increase their risk of uterine cancer.
National Cancer Institute

Contact: Jim Ritter
jritter@lumc.edu
708-216-2445
Loyola University Health System

Showing releases 126-150 out of 1352.

<< < 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 > >>

  Search News Releases

     

 

EurekAlert!